Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02291913
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
Phase II Study of Everolimus Beyond Progression
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT02269670
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Testosterone Regulation of the Natriuretic Peptide System
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02269072
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 493
- Registration Number
- NCT02246621
- Locations
- 🇦🇹
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, Austria
🇯🇵Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
Endocrine Response in Women With Invasive Lobular Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Priscilla McAuliffe
- Target Recruit Count
- 201
- Registration Number
- NCT02206984
- Locations
- 🇺🇸
Univ. of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸ALBERT EINSTEIN COLLEGE OF MEDICINE Montefiore Medical Center, Bronx, New York, United States
🇺🇸Josh Plassmeyer, Pittsburgh, Pennsylvania, United States
Bay98-7196, Dose Finding / POC Study
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 319
- Registration Number
- NCT02203331
ER Reactivation Therapy for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 19
- Registration Number
- NCT02188745
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Fudan University
- Registration Number
- NCT02140437
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.